Par Enters Generic Injectable Market Via JHP Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The generics maker is expanding its portfolio of reformulations through the acquisition of privately-held JHP in a deal worth $490 million, expected to close in short order.